Literature DB >> 9159310

No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients.

G Dumoulin1, B Hory, N U Nguyen, C Bresson, V Fournier, M Bouhaddi, J M Chalopin, Y Saint-Hillier, J Regnard.   

Abstract

Although hyperparathyroidism is a common feature in renal transplant recipients, the long-term course of parathyroid hormone (PTH) secretion in these patients is not well established, and the actual contribution of PTH to posttransplant bone disease remains incompletely understood. Therefore, we studied calcium-regulating hormones and serum osteocalcin, as a marker of bone remodeling, in 82 normocalcemic renal transplant recipients with good renal function who had received a graft 6 to 73 months previously and in 82 healthy subjects matched for age and sex. In all subjects, fasting serum and 24-hour urinary samples were collected. The transplant recipients had excessive PTH secretion (serum PTH, 6.9 +/- 0.5 pmol/L in recipients v 3.0 +/- 0.1 pmol/L in healthy subjects; P < 0.001) and high bone turnover (osteocalcin, 16.6 +/- 0.8 microg/L v 8.0 +/- 0.3 microg/L; P < 0.001). (Values are mean +/- SEM.) In addition, transplant recipients had a slightly higher ionized calcium than the healthy subjects, providing definite evidence of an inappropriate PTH secretion in renal transplant recipients. Furthermore, in subgroups of 25 recipients and 25 healthy controls matched for creatinine clearance, the results superimposed those obtained in the whole groups, suggesting that excessive PTH secretion and high bone turnover in renal transplant recipients did not merely reflect the moderately reduced renal function of some recipients. In the whole group of transplant recipients, PTH correlated positively with osteocalcin (r = 0.40; P < 0.001), suggesting that PTH contributes at least partly to posttransplant bone disease. Conversely, there was no correlation between serum PTH or osteocalcin and the delay from grafting. Therefore, our results provide no evidence for a spontaneous improvement of either persistent hyperparathyroidism or high bone turnover in normocalcemic long-term renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159310     DOI: 10.1016/s0272-6386(97)90129-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.

Authors:  Greg Knoll; Sandra Cockfield; Tom Blydt-Hansen; Dana Baran; Bryce Kiberd; David Landsberg; David Rush; Edward Cole
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

2.  Parathyroid hormone levels in long-term renal transplant children and adolescents.

Authors:  Isabella Guzzo; Giacomo Di Zazzo; Chiara Laurenzi; Lucilla Ravà; Germana Giannone; Stefano Picca; Luca Dello Strologo
Journal:  Pediatr Nephrol       Date:  2011-05-10       Impact factor: 3.714

3.  Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism.

Authors:  Simon D Roe; Christine J Porter; Ian M Godber; David J Hosking; Michael J Cassidy
Journal:  Osteoporos Int       Date:  2004-07-16       Impact factor: 4.507

4.  Vitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years.

Authors:  Frank-Peter Tillmann; Carolin Wächtler; Anita Hansen; Lars Christian Rump; Ivo Quack
Journal:  Transplant Res       Date:  2014-12-31

5.  Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients.

Authors:  Marius C Florescu; Km Monirul Islam; Troy J Plumb; Sara Smith-Shull; Jennifer Nieman; Prasanti Mandalapu
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-05-14

Review 6.  Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion.

Authors:  Sandro Giannini; Sandro Mazzaferro; Salvatore Minisola; Luca De Nicola; Maurizio Rossini; Mario Cozzolino
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.